SAN DIEGO, April 6, 2021 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Michael E. Faerm as Chief Financial Officer. Mr. Faerm brings more than 20 years of life sciences, equity research, and investment banking experience….
SAN DIEGO, February 26, 2021 — Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other…
Collaboration utilizes Artiva’s proprietary off-the-shelf allogeneic NK cell and CAR technology platforms to develop up to three CAR-NK cell therapies targeting solid tumor-associated antigens Artiva to receive $30 million upfront payment and up to $612 million per program in potential future development and commercial milestones, and royalties on any future worldwide product sales Artiva to…
SAN DIEGO, January 5, 2021 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the…
AB-101 is an optimized universal NK cell therapy candidate designed for clinical use with tumor-targeted therapeutics First clinical program applying Artiva’s proprietary large-scale NK-cell manufacturing process for off-the-shelf cellular therapies SAN DIEGO, December 7, 2020 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to…
Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets Proof of concept, preclinical assessment to establish activity and feasibility of the combination of Artiva’s allogeneic natural killer (NK) cells and Affimed’s innate cell engagers (ICE®) San Diego and Heidelberg, Germany, November 5, 2020…
Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure First clinical study planned for later this year followed by two additional clinical programs SAN DIEGO, June 26, 2020 – Artiva Biotherapeutics, Inc.,…